Article révisé par les pairs
Titre:
  • Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Auteur:Biganzoli, Laura; Cufer, T; Bruning, Peter; Coleman, R; Duchateau, L; Rapoport, Benjamin; Nooij, Marianne; Delhaye, François; Miles, David J C; Sulkes, Aaron; Hamilton, Andrew; Piccart-Gebhart, Martine
Informations sur la publication:Cancer, 97, 1, page (40-45)
Statut de publication:Publié, 2003-01
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Cardiac toxicity
Doxorubicin
Multicenter trials
Paclitaxel
MeSH keywords:Adenocarcinoma -- drug therapy
Adenocarcinoma -- secondary
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Cyclophosphamide -- administration & dosage
Disease Progression
Disease-Free Survival
Doxorubicin -- administration & dosage
Female
Follow-Up Studies
Heart -- drug effects
Humans
Middle Aged
Paclitaxel -- administration & dosage
Risk Factors
Safety
Survival Rate
Treatment Outcome
Note générale:Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
FLWIN
Langue:Anglais
Identificateurs:urn:issn:0008-543X
info:doi/10.1002/cncr.10914
info:scp/0037216170
info:pmid/12491503

Documents en relation

DI-fusion